Position in NGNE
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$263,771
+$6,651 QoQ
Shares Held
8,387
-34.2% QoQ
Ownership
0.042%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#64
of 112 holders
Holding Since
Mar 2024
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NGNE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Brevan Howard Capital Management LP holds $183,834,510 across 129 Biotechnology names. NGNE ranks #97 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ROIV |
Roivant Sciences Ltd.
|
517,621 | $18,318,607 | |
| 2 | MRNA |
Moderna, Inc.
|
181,105 | $12,682,782 | |
| 3 | BBIO |
BridgeBio Pharma, Inc.
|
155,727 | $11,598,546 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
17,622 | $8,753,376 | |
| 5 | AXSM |
Axsome Therapeutics, Inc.
|
31,928 | $7,815,015 | |
| 6 | DFTX |
Definium Therapeutics, Inc.
|
156,812 | $7,376,435 | |
| 7 | SNDX |
Syndax Pharmaceuticals Inc
|
309,065 | $6,756,160 | |
| 8 | INCY |
Incyte Corp
|
45,270 | $5,131,807 |
All Filings in NGNE
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $263,771 | 8,387 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $257,120 | 12,754 | Shares | Defined | 2026-05-15 | |
| 2025-09-30 | $223,175 | 12,878 | Shares | Defined | 2025-11-14 | |
| 2024-03-31 | $410,457 | 8,064 | Shares | Defined | 2024-05-15 | |
| No filing history on record for this holder in this stock. | ||||||